CSO, Head of Bioinformatics Asuragen, a Bio-Techne Brand
ESR1 mutations are the leading cause of primary treatment resistance in HR+ metastatic Breast Cancer (mBC). Up to 40% of HR+ mBC patients on Aromatase Inhibitors will develop ESR1 mutations. ESR1 mutations in the ligand-binding domain leads to constitutive activation of the estrogen receptor (ER) in the absence of estrogen, thus via ESR1 mutations, estrogen-dependent disease becomes an estrogen-independent disease. In this workshop, we will showcase the design and performance of the QuantideX® qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA/exosomal RNA Isolation Kit to deliver sensitivity of ≤0.1% for 11 ESR1 mutations located in the ligand-binding domain, utilizing the power of cfDNA and exosomal RNA isolated from exosomes to deliver best in class performance.
